Kura Oncology Logo
Kura Oncology to Participate in Two Upcoming Investor Conferences
07 sept. 2021 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Logo
Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
06 juil. 2021 07h30 HE | Kura Oncology, Inc.
– Combination of tipifarnib and alpelisib shows robust activity in preclinical PDX models of HRAS and PIK3CA pathway dependent tumors – – HNSCC accounts for more than 500,000 new cancer cases each...
Kura Oncology Logo
Kura Oncology Appoints Carol Schafer to Board of Directors
04 juin 2021 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Logo
Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit
13 mai 2021 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Logo
Kura Oncology Reports First Quarter 2021 Financial Results
06 mai 2021 16h04 HE | Kura Oncology, Inc.
– Menin inhibitor KO-539 continues to demonstrate compelling clinical activity, favorable safety/tolerability and a wide therapeutic window – – KOMET-001 trial amended to include Phase 1b expansion...
Kura Oncology Logo
Kura Oncology to Report First Quarter 2021 Financial Results
29 avr. 2021 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Logo
Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma
29 mai 2020 08h00 HE | Kura Oncology, Inc.
– Median OS of 15.4 months, median PFS of 5.9 months and ORR of 50% observed in recurrent/metastatic HRAS mutant HNSCC – – Outcomes with approved therapies are poor, with reported median OS of 5-8...
Kura Oncology Logo
Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program
13 mai 2020 17h00 HE | Kura Oncology, Inc.
SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Logo
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
08 mai 2020 16h03 HE | Kura Oncology, Inc.
SAN DIEGO, May 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Logo
Kura Oncology to Present at BofA Securities Virtual Health Care Conference 2020
07 mai 2020 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...